Marco Donia
Herlev, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 187 publications
Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.
Journal: Journal for immunotherapy of cancer
Published: July 27, 2026
Response to letter Re: "Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth".
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 03, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.
Journal: Journal for immunotherapy of cancer
Published: June 10, 2026
Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 21, 2026
Controversies in upper gastrointestinal cancers: adoptive cell therapies.
Journal: ESMO gastrointestinal oncology
Published: April 17, 2026
Prognostic dynamics of pathological complete response and ctDNA clearance after neoadjuvant/perioperative immunotherapy in cancer: a reconstructed individual patient analysis.
Journal: Journal of the National Cancer Institute
Published: April 09, 2026
Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 22, 2026
Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 19, 2026
Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.
Journal: Journal of the National Cancer Institute
Published: March 09, 2026
Receptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen.
Journal: Signal transduction and targeted therapy
Published: February 20, 2026
Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.
Journal: International journal of cancer
Published: January 28, 2026
Corrigendum to "Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028": [ESMO Open 10 (2025) 104295].
Journal: ESMO open
Published: January 03, 2026
Last Updated: 09/26/2026